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Neutrophils are the most abundant white blood cell in blood 
and play a critical role in preventing infections as part of the 
innate immune system. Reduction in neutrophils below an 
absolute count of 500 cells/μL is termed severe neutropenia or 
agranulocytosis. Drug-induced immune neutropenia (DIIN) 
occurs when drug-dependent antibodies form against neutrophil 
membrane glycoproteins and cause neutrophil destruction. 
Affected patients have fever, chills, and infections; severe 
infections left untreated can result in death. Treatment with 
granulocyte colony-stimulating factor can hasten neutrophil 
recovery. Cumulative data show that severe neutropenia or 
agranulocytosis associated with exposure to nonchemotherapy 
drugs ranges from approximately 1.6 to 15.4 cases per million 
population per year. Drugs most often associated with 
neutropenia or agranulocytosis include dipyrone, diclofenac, 
ticlopidine, calcium dobesilate, spironolactone, antithyroid 
drugs (e.g., propylthiouracil), carbamazepine, sulfamethoxazole-
trimethoprim, β-lactam antibiotics, clozapine, levamisole, 
and vancomycin. Assays used for detection of neutrophil 
drug-dependent antibodies (DDAbs) include flow cytometry, 
monoclonal antibody immobilization of granulocyte antigens, 
enzyme-linked immunosorbent assay, immunoblotting, 
granulocyte agglutination, and granulocytotoxicity. However, 
testing for neutrophil DDAbs is rarely performed owing to its 
complexity and lack of availability. Mechanisms proposed for 
DIIN have not been rigorously studied, but those that have been 
studied include drug- or hapten-induced antibody formation 
and autoantibody production against drug metabolite or protein 
adducts covalently attached to neutrophil membrane proteins. 
This review will address acute, severe neutropenia caused by 
neutrophil-reactive antibodies induced by nonchemotherapy 
drugs—DIIN. Immunohematology 2014;30:95–101.
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Drug-Induced Immune Neutropenia
Neutrophils (polymorphonuclear leukocytes [PMNs]) are 
a type of granulocyte and are the major class of white blood 
cells (WBCs) in human peripheral blood. The circulation of 
a healthy human adult contains 4500 to 10,000 WBCs/µL 
with approximately 60 percent or more being neutrophils.1 
A healthy adult produces 1 × 1011 neutrophils each day, each 
of which survives about 6 to 8 hours in the circulation.2 
Neutrophils play an important role in the innate immune 
response and are critical to host defense against infectious 
disease. They circulate in the blood until recruited by 
chemical signals to sites of infection, where they function as 
phagocytes that engulf and kill extracellular pathogens with 
their microbicidal arsenal. Macrophages also contribute 
significantly to this process. Because of their important role in 
preventing infections, disorders that result in a significant lack 
of neutrophils put the host at risk of severe illness and even 
death. A reduction of neutrophils (segmented and band cells) 
in the blood circulation to less than an absolute neutrophil 
count (ANC) of 1000 to 1500/μL is considered neutropenia. 
An ANC less than 500/μL is considered severe neutropenia 
or agranulocytosis, and individuals with an ANC less than 
100/μL are at severe risk of morbidity and mortality from 
infections.3,4 The terms “agranulocytosis” and “neutropenia” 
are often used interchangeably, but some argue that use of the 
term “agranulocytosis” should be reserved for conditions in 
which the bone marrow cannot make sufficient granulocytes, 
and “neutropenia” when just neutrophils fall below normal 
levels.5 For the purposes of this review, the terms will be used 
synonymously, with agranulocytosis representing cases of 
severe neutropenia in which the ANC is less than 100/μL.
Like thrombocytopenia and anemia, neutropenia can be 
induced after exposure to myriad drugs6 and results from either 
decreased production or increased destruction of neutrophils. 
Decreased production is usually a consequence of exposure 
to chemotherapeutic drugs causing immune suppression 
of bone marrow myeloid precursors. Idiosyncratic or acute 
neutropenia resulting from increased neutrophil destruction is 
commonly caused by adverse reactions to nonchemotherapy 
drugs.3,4,7
Clinical Features, Diagnosis, and Treatment
Drug-induced immune neutropenia (DIIN) is typically 
suspected when a sudden severe drop in neutrophils (ANC 
<500/μL) occurs shortly after repeat exposure to a drug or 
5 to 7 days after first exposure. Patients’ symptoms include, 
but are not limited to, fever, chills, nonspecific sore throat, 
and myalgia or arthralgia. Diagnosis is difficult because 
patients often are asymptomatic before severe neutropenia 
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is discovered, usually from a blood count performed for 
another reason.8 Without treatment, patients can experience 
severe infections, septicemia, and septic shock that can lead to 
death in 2 to 10 percent of cases.4,7 In DIIN, the bone marrow 
typically shows normal or mild hypocellularity with decreased 
or absent myeloid precursor cells, or it can be hypercellular 
with neutrophilic maturation arrest.8
Criteria for drug imputability are the same as those applied 
in drug-induced immune thrombocytopenia or anemia: (1) 
exposure to the candidate drug preceded neutropenia, (2) 
recovery from neutropenia was complete and sustained after 
discontinuing candidate drug, (3) candidate drug was the only 
drug used before the onset of neutropenia or other drugs were 
continued or reintroduced after discontinuation of candidate 
drug with a sustained neutrophil count, and (4) other causes 
of neutropenia were excluded.
Treatment of patients with DIIN begins with immediate 
withdrawal of the implicated drug. Further treatment consists 
of supportive care for complications such as fever and 
infections, which may include analgesics and antibiotics for 
severe infections (ANC <100/μL) and antifungal agents for 
fungal infections. Treatment with recombinant granulocyte 
colony-stimulating factor (G-CSF) in severe infections can 
hasten neutrophil recovery and shorten neutropenic fever, but 
is more often used in neutropenia induced by chemotherapy.4,7,9 
Granulocyte transfusions are typically not required in DIIN, 
and the risk–benefit is not favorable.9
Incidence and Drugs Most Frequently Implicated
In 1980, the International Agranulocytosis and Aplastic 
Anemia Study (IAAAS), a population-based case-controlled 
surveillance program, was coordinated, which involved Israel 
and seven regions of Europe.10 The most recent analysis of 
these data shows that the frequency of agranulocytosis in 
patients receiving nonchemotherapy drugs is approximately 
5 cases/million population per year.11 Cumulative data 
from IAAAS, case reports, and clinical trials show that 
agranulocytosis associated with drug exposure ranges 
from approximately 1.6 to 15.4 cases per million population 
per year.4,7,9,11–13 Drug-associated neutropenia frequency 
increases with age, being highest in people older than 65 
years, and the incidence is also higher in women.11 Drugs 
most often associated with neutropenia include dipyrone 
(metamizole), diclofenac, ticlopidine, calcium dobesilate, 
spironolactone, antithyroid drugs (e.g., propylthiouracil), 
carbamazepine, quinine, sulfamethoxazole-trimethoprim, 
β-lactam antibiotics, clozapine, levamisole, and vancomycin 
(Table 1).11,14 Neutropenia incidence is higher for a select 
number of drugs.
Propylthiouracil is used to treat hyperthyroidism (Graves 
disease) by decreasing the levels of thyroid hormone. Mild 
leukopenia (WBCs <4000/μL) occurs in 12 percent of adults 
and 25 percent of children receiving proplylthiouracil,15 but 
severe neutropenia occurs less frequently (0.31%).16
A careful review of a 7-year period of 114 patients receiving 
home intravenous vancomycin therapy in New Mexico found 
12 percent developed vancomycin-induced neutropenia and 
3.5 percent had drops in ANC to 500/μL or less.17
The anthelmintic agent levamisole has been known to 
cause agranulocytosis or neutropenia in exposed patients 
since the 1970s,18 primarily in individuals using cocaine 
adulterated with levamisole,19,20 but also when used as adjuvant 
chemotherapy in patients with colorectal cancer.21 Drug 
Enforcement Administration (DEA) reports in 2009 showed 
69 percent of seized cocaine was contaminated with as much 
as 10 percent levamisole.22 Neutropenia has been reported 
to occur in as many as 13 percent of patients exposed to 
levamisole.22 In cancer trials, agranulocytosis associated with 
levamisole showed dose dependence, with agranulocytosis 
developing in 3.1 percent of patients receiving 2.5 mg/kg for 
2 consecutive days every week compared with 0.1 percent 
receiving the same dosage for 3 consecutive days but every 
other week.22
Clozapine-induce neutropenia occurs in about 1 
percent of patients during the first 3 months of treatment.3 
Clozapine, a dibenzodiazepine, is an atypical antipsychotic 
medication used in the treatment of schizophrenia resistant to 
conventional neuroleptics. Clozapine is perhaps the drug most 
often associated with agranulocytosis or neutropenia, and it 
carries five black box warnings alerting physicians to that risk 
and several other adverse effects of the drug. However, the 
mechanism responsible for severe neutropenia after exposure 
to clozapine is not immune mediated, but is the result of ATP 
depletion through formation of an active nitrenium metabolite 
that causes apoptotic destruction of neutrophils.5,23
Whereas the overall incidence of drug-induced 
neutropenia or agranulocytosis has been examined, the 
incidence of specifically DIIN is not well defined. This is 
primarily related to the difficulty in distinguishing drug-
induced neutropenia caused by myelosuppression and direct 
neutrophil cytotoxicity from immune mechanisms, and poor 
sensitivity and availability of laboratory testing for detection 
of drug-dependent neutrophil antibodies.8 Table 1 lists those 
drugs that have most often been reported to cause DIIN.
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Laboratory Testing for Drug-Dependent Neutrophil 
Antibodies
As just mentioned, unlike for drug-induced immune 
thrombocytopenia and anemia, laboratory testing for neutro-
phil drug-dependent antibodies (DDAbs) is not as productive, 
and testing for neutrophil antibodies is not widely available. 
The reasons for this are that neutrophil antibody testing 
is technically complex, labor-intensive, and expensive. In 
addition, the inability to maintain the integrity of neutrophils 
Table 1. Nonchemotherapy drugs reported to be associated with drug-induced neutropenia
Stroncek et al.8* Berliner et al.14† Tesfa et al.5† BloodCenter of Wisconsin‡
aminopyrine carbamazepine alimemazine cefepime
aminosalicylic acid carbimazole calcium dobesilate ceftriaxone
amodiaquine cephalosporins cefepime ciprofloxacin
amoxicillin chloramphenicol clozapine clindamycin
ampicillin methimazole etanercept ibuprofen
aprindine penicillins fluconazole levetiracetam
carbimazole sulfonamides furosemide piperacillin-tazobactam
cefotaxime thiouracil infliximab quetiapine
ceftazidime valproic acid IVIG sulfamethoxazole-trimethoprim
cefuroxime ketoconazole tacrolimus
cephradine lamotrigine vancomycin

























*Drugs reported to be associated with drug-induced immune neutropenia.
†Drugs reported to be highly associated with agranulocytosis.
‡ Drugs in 2012 for which sera from patients with suspicion of drug-induced immune neutropenia were tested for antibodies in a flow cytometry assay by 
Platelet & Neutrophil Immunology Lab, BloodCenter of Wisconsin, Milwaukee. No drug-dependent antibodies involving these drugs were detected in any of 
the patients’ sera.
IVIG = intravenous immunoglobulin G.
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for testing by storage at 4°C or by cryopreservation requires 
that cells be isolated from fresh blood each day. This demands 
the regular availability of large numbers of blood donors. For 
these reasons, it is critical that granulocyte antibody and 
antigen testing be performed by an experienced laboratory 
using appropriate controls. When neutrophil DDAb testing is 
performed, methods used are very similar to those used for 
testing of platelet DDAbs with substitution of freshly isolated 
neutrophils for platelets. A typical assay consists of incubation 
of isolated neutrophils with patient’s serum in the presence or 
absence of the implicated drug, followed by washing of cells 
incubated with drug with washes containing drug and those 
not incubated with drug, just with buffer. Neutrophils are then 
incubated with fluorescent or enzyme-labeled anti-human 
immunoglobulin (Ig)G or anti-human IgM for detection 
of bound DDAbs. Flow cytometry for immunofluorescent 
detection of DDAbs (Fig. 1) and monoclonal antibody 
immobilization of granulocyte antigens (MAIGA) assay for 
enzyme-linked immunosorbent assay (ELISA) detection and 
determination of the neutrophil glycoproteins targeted by 
DDAbs are methods in current use.20,24–27 Other methods that 
have been used are immunoblotting, granulocyte agglutination 
test (GAT), and granulocytotoxicity.8 Despite the availability of 
these various methods, neutrophil DDAbs, with the exception 
of those induced by quinine,8,25,26,28,29 are rarely detected. The 
paucity of neutrophil DDAbs detected suggests that currently 
used tests lack sensitivity or that mechanisms responsible 
for drug-induced neutropenia often do not involve antibody 
formation (see next section on Pathogenic Mechanisms).
Like some platelet and red blood cell DDAbs,30,31 
neutrophil DDAbs that can only be detected in the presence of 
drug metabolites have also been reported.32 Another issue is 
that, in the small number of cases in which patient sera have 
been tested, often the sera were tested without the addition 
of drug so that only nondrug antibodies were detected. The 
presence of non-DDAbs in suspected cases of DIIN suggests a 
drug-induced autoantibody mechanism is responsible for the 
patient’s neutropenia. In vitro assays demonstrating DDAbs 
that inhibit the growth of myeloid progenitor cells have also 
been reported.33
The neutrophil glycoprotein targets of DDAbs have not 
been well studied for most drugs. Stroncek et al.,28 using 
immunoprecipitation, showed that a quinine-dependent 
antibody targeted the neutrophil-specific protein CD177 
and another unidentified glycophosphatidylinositol-linked 
membrane glycoprotein. Meyer et al.27 found a cefotaxime 
DDAb targeted CD11b and CD35 and a metamizole DDAb 
directed against CD16.
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Fig. 1 Fluorescence histograms generated from immunofluorescence detection of immunoglobulin G (IgG) drug-dependent neutrophil 
antibodies by flow cytometry. Normal isolated neutrophils were incubated with sera and washed, and neutrophil-bound antibodies were 
detected with fluorescent anti-human IgG. (A) Normal serum incubated with neutrophils in the presence of either quinine (black histograms) 
or buffer (white histograms) shows low IgG fluorescence, indicating no antibodies are present. (B) Serum from a patient exposed to quinine 
with drug-induced neutropenia incubated with neutrophils showing high IgG fluorescence (MFI = 69.8) only with quinine, indicating the 
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Pathogenic Mechanisms
Mechanisms of drug-dependent antibody formation and 
binding to neutrophils have not been rigorously studied, and 
proposed mechanisms are largely unsubstantiated. However, 
some of the mechanisms proposed to explain DDAbs formed 
against platelets (see article in this issue of the journal) 
probably also apply to those against neutrophils, but this has 
not been proven. Greater study has been made of mechanisms 
to explain nonimmunologic drug-induced neutropenia or 
agranulocytosis. Proposed mechanisms of immunologic and 
nonimmunologic drug-induced neutropenia include oxidation 
of drugs by neutrophil reactive oxygen species (ROS), causing 
the formation of toxic metabolites or haptens, cytotoxicity by 
large granular T lymphocytes (T-LGL), disruptions of granul-
opoiesis and egress of neutrophils from the bone marrow, 
hapten- or drug-specific antibodies, formation of drug-induced 
autoantibodies, and genetic and epigenetic modifications that 
predispose an individual to drug sensitivity.5,8 Mechanisms 
specific for DIIN will be discussed next.
Drug Oxidation
It is essential that drugs undergo biotransformation, 
primarily in the liver, into water-soluble metabolites that 
can be excreted in the urine to prevent cellular accumulation 
and toxicity.34 Biotransformation gives rise to reactive 
intermediates and metabolites that can readily make 
covalent linkages with cellular proteins, including neutrophil 
membrane glycoproteins.22 It is also possible that neutrophil 
enzymes such as myeloperoxidase (MPO) could be capable 
of producing reactive drug metabolites.22 Once formed 
and attached to neutrophil proteins, these molecules could 
elicit drug-specific antibody production through a hapten 
mechanism or by production of autoantibodies targeting 
drug–protein adducts.5,22 Several drugs associated with a 
significant incidence of agranulocytosis (e.g., methimazole,22 
propylthiouracil,22 capatopril,22 levamisole,22 clozapine5,22) 
have been reported to form drug–protein adducts in vitro, 
although in contrast, structurally related drugs are rarely 
associated with agranulocytosis.22
Hapten Mechanism
Haptens are low-molecular-weight (usually <5000 daltons) 
molecules that are not capable of eliciting an immune response 
unless they are coupled to a larger carrier protein. Drugs like 
penicillin and some cephalosporin drugs when covalently 
linked to cell surface proteins can elicit drug-specific/hapten 
antibodies. This mechanism is well described for DDAbs 
targeting red blood cells (RBCs), which cause immune 
hemolytic anemia,35 but has not been proven to occur in drug-
induced thrombocytopenia.36 As mentioned in the previous 
section, several drugs highly associated with agranulocytosis 
do form drug–protein adducts with neutrophil membrane 
glycoproteins that could elicit hapten-specific (drug-specific) 
antibodies that destroy neutrophils.37 Hapten antibodies were 
reported to cause DIIN in patients exposed to flecanide38 and 
dipyrone.39
Immune Complex Mechanism
Fc-receptors (FcR) are a family of related protein molecules 
expressed on various cells in the body that engage the Fc portion 
of immunoglobulins (antibodies) and regulate activation 
or inhibition of various cellular functions important in the 
immune response, including phagocytosis, immunoglobulin 
transport, and prevention of IgG catabolism.40 Resting 
neutrophils express FcγRIIIb and FcγRIIa receptors and 
express FcγRI receptors when induced by various neutrophil-
activating stimuli.41 Therefore, neutrophils are capable of 
binding immune complexes of DDAbs and drug, but this 
mechanism has not been proven for DIIN.
Autoantibody Mechanism
Autoantibodies produced against platelets and RBCs have 
been reported after exposure to gold salts and α-methyldopa, 
respectively.42 In some cases of suspected DIIN, neutrophil-
reactive antibodies are detected that do not depend on the 
presence of drug.20,43,44 It is possible that these non–drug-
dependent antibodies could be true autoantibodies induced 
by the drug. Demonstration that serum from such patients 
reacts with autologous neutrophils collected once their 
ANCs normalize would be one way to confirm these are true 
autoantibodies, but there are no known reports in which such 
testing has been performed.
Summary
DIIN can occur in susceptible individuals 5 to 7 days after 
first exposure to a drug. Those affected typically experience 
acute, severe neutropenia or agranulocytosis (ANC <500/μL) 
and symptoms of fever, chills, sore throat, and muscle and 
joint pain. Although difficult to diagnosis, it is important to 
identify DIIN because, if left untreated, mortality is as high as 
10 percent in cases exhibiting severe infections. Idiosyncratic 
drug-induced neutropenia or agranulocytosis occurs with 
a frequency of approximately 1.6 to 15.4 cases per million 
population per year, and is higher in the elderly and women. 
Drug-induced immune neutropenia
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The classes of drugs most commonly involved in DIIN include 
analgesics, antiarrhythmic agents, antibiotics, antimalarials, 
and antithyroid agents. Laboratory testing for neutrophil 
DDAbs as confirmation of DIIN is rarely performed owing to the 
difficulty and low sensitivity of tests used and the lack of testing 
availability. Flow cytometry, MAIGA, GAT, immunoblotting, 
and granulocyte cytotoxicity methods have been used to 
detect DDAbs. Some DDAbs target myeloid progenitor cells 
and cause neutropenia by inhibiting neutrophil production. 
Neutrophil glycoprotein targets that have been described 
for DDAbs include CD11b, CD16, CD35, and CD177. 
Mechanisms of drug-dependent antibody formation and 
binding to neutrophils have not been rigorously studied, 
and proposed mechanisms are largely unsubstantiated. 
Mechanisms that have been proposed include destruction 
of neutrophils by hapten/drug-specific antibodies, and auto-
antibodies that bind adducts of drug metabolites bound to 
neutrophil membrane proteins formed after biotransformation 
of drugs, although several of the other mechanisms of drug-
dependent antibody formation that have been described as 
causative of drug-induced immune thrombocytopenia could 
also possibly be involved in DIIN.
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